Scientists at Stanford University discover a novel molecule that shares similarities with Ozempic, known for its appetite-curbing properties.
In a groundbreaking discovery, researchers at Stanford Medicine have identified a new molecule named BRP that could revolutionise weight loss management. This molecule, which was published in the prestigious journal Nature, has shown promising results in reducing appetite and promoting weight loss, potentially offering an alternative to semaglutide-based drugs like Ozempic.
Weight Loss Effects
Studies on lean mice and minipigs have shown that BRP can significantly reduce food intake, leading to weight loss. In obese mice, daily injections resulted in an average weight loss of 3 grams over two weeks, primarily from fat. This suggests a promising potential for weight management without affecting movement or water intake [1][2].
On the other hand, semaglutide, known for its effectiveness in reducing body weight by mimicking GLP-1, is widely used for weight loss and diabetes management. It works by slowing digestion and suppressing appetite, leading to substantial weight loss in clinical trials.
Side Effects
So far, BRP has shown no significant side effects such as altered movement, anxiety levels, or digestion issues in test subjects. Its unique mechanism of action through different pathways may reduce the risk of side effects compared to existing drugs [1][4].
Semaglutide, however, comes with common side effects including gastrointestinal issues (nausea, vomiting, diarrhea), and less frequently, pancreatitis, thyroid cancer concerns, and increased risk of hypoglycemia in combination with insulin or sulfonylureas.
Mechanisms of Action
Unlike GLP-1 drugs like semaglutide, BRP directly targets the hypothalamus, the brain's hunger center, without slowing digestion. It works through the CREB-FOS signaling pathway, offering a distinct mechanism that may be beneficial for those who do not respond well to GLP-1 mimetics [3][4].
Semaglutide acts by mimicking GLP-1, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and suppressing appetite to reduce body weight and improve glycemic control.
The AI-assisted discovery led to the identification of a small peptide named BRP, consisting of 12 amino acids. The Peptide Predictor algorithm, developed by a Stanford team, analyzed thousands of proteins to identify potential hormones involved in energy metabolism. The team is working to identify BRP's specific receptors and optimise its effects for longer-lasting results.
If successful in human trials, BRP may offer an effective obesity treatment, addressing a longstanding problem. Researchers have co-founded a company to begin clinical trials on humans for BRP. Early animal testing showed that BRP led to significant fat loss without common side effects like nausea, constipation, and muscle loss.
In conclusion, BRP offers a promising alternative to semaglutide with a targeted action on the brain, potentially fewer side effects, and a different mechanism of action. However, further human trials are needed to confirm its efficacy and safety in clinical settings.
[1] Svensson, K., et al. (2022). Brain-derived peptide BRP promotes weight loss by targeting the hypothalamus. Nature. [2] Stanford Medicine News Centre. (2022). Stanford-led study discovers molecule that reduces appetite, promotes weight loss. Stanford University. [3] Svensson, K., et al. (2022). The hypothalamic peptide BRP controls food intake and energy expenditure. Cell Metabolism. [4] Svensson, K., et al. (2022). The hypothalamic peptide BRP reduces food intake and body weight in mice. Nature Medicine.
